CA2233309A1 - Recombinant hepatitis c virus rna replicase - Google Patents

Recombinant hepatitis c virus rna replicase Download PDF

Info

Publication number
CA2233309A1
CA2233309A1 CA002233309A CA2233309A CA2233309A1 CA 2233309 A1 CA2233309 A1 CA 2233309A1 CA 002233309 A CA002233309 A CA 002233309A CA 2233309 A CA2233309 A CA 2233309A CA 2233309 A1 CA2233309 A1 CA 2233309A1
Authority
CA
Canada
Prior art keywords
rdrp
hcv
ala
leu
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002233309A
Other languages
English (en)
French (fr)
Inventor
Curt H. Hagedorn
Reinoldus H. Al
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2233309A1 publication Critical patent/CA2233309A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/127RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002233309A 1995-09-27 1996-09-27 Recombinant hepatitis c virus rna replicase Abandoned CA2233309A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US438395P 1995-09-27 1995-09-27
US60/004,383 1995-09-27

Publications (1)

Publication Number Publication Date
CA2233309A1 true CA2233309A1 (en) 1997-04-03

Family

ID=21710540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002233309A Abandoned CA2233309A1 (en) 1995-09-27 1996-09-27 Recombinant hepatitis c virus rna replicase

Country Status (8)

Country Link
US (2) US5981247A (enExample)
EP (1) EP0859833B1 (enExample)
JP (1) JP4191797B2 (enExample)
AT (1) ATE318896T1 (enExample)
AU (1) AU719122B2 (enExample)
CA (1) CA2233309A1 (enExample)
DE (1) DE69635864T2 (enExample)
WO (1) WO1997012033A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
FR2761695B1 (fr) 1997-04-04 1999-09-24 Bio Merieux Arn polymerase fonctionnant preferentiellement sur matrice d'arn, sa preparation et son utilisation
CA2312484A1 (en) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
KR100954390B1 (ko) 1998-02-25 2010-04-26 에모리 유니버시티 2'-플루오로뉴클레오사이드
WO1999051781A1 (en) * 1998-04-02 1999-10-14 Viropharma Incorporated Hepatitis c virus ns5b compositions and methods of use thereof
US6639053B1 (en) 1998-06-24 2003-10-28 Tetsuya Toyoda HCV-derived RNA polymerase gene
AU2181800A (en) * 1998-12-10 2000-06-26 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US7018796B2 (en) * 2000-04-07 2006-03-28 Shionogi & Co., Ltd. Preincubation assay methods
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
GB0029539D0 (en) * 2000-12-04 2001-01-17 Isis Innovation Method for identifying modulatorss of transcription
JP2004537271A (ja) * 2001-01-31 2004-12-16 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー Rna依存性rnaポリメラーゼ(rdrp)ウイルスの複製のためのインビトロ系
US7452705B2 (en) * 2001-05-22 2008-11-18 The University Of Chicago N4 virion single-stranded DNA dependent RNA polymerase
AU2002325755A1 (en) * 2001-09-18 2003-04-01 Affinium Pharmaceuticals, Inc. Methods and apparatuses for purification
WO2003027330A1 (en) * 2001-09-25 2003-04-03 Xencor Rna dependent rna polymerase mediated protein evolution
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
KR100447578B1 (ko) * 2001-11-01 2004-09-07 주식회사 이매진 Hcv 자가 복제 효소 활성의 세포내 측정용 키트 및측정 방법
US20030114409A1 (en) * 2001-11-16 2003-06-19 Mello Craig C. Facilitation of RNA interference
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN104193791A (zh) 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
WO2004046331A2 (en) 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
DE602004028841D1 (de) 2003-07-25 2010-10-07 Centre Nat Rech Scient Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
WO2005070957A1 (en) * 2004-01-09 2005-08-04 Merck & Co., Inc. Hcv rna-dependent rna polymerase
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
CA2597685A1 (en) 2005-02-28 2006-09-08 Genelabs Technologies, Inc. Tricyclic-nucleoside compounds for treating viral infections
TW200720285A (en) 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2010014134A1 (en) 2008-07-02 2010-02-04 Idenix Pharamaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2166016A1 (en) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011023801A1 (en) 2009-08-31 2011-03-03 F. Hoffmann-La Roche Ag Hcv ns3/4a replicon shuttle vectors
MX2012005528A (es) 2009-11-14 2012-06-12 Hoffmann La Roche Biomarcadores para pronosticar rapida respuesta a tratamiento hcv.
KR20120085877A (ko) 2009-12-02 2012-08-01 에프. 호프만-라 로슈 아게 Hcv 치료에 대한 지속된 반응을 예측하기 위한 생체마커
US20110245328A1 (en) 2010-03-31 2011-10-06 Hyunsoon Kang HCV NS5A Replicon Shuttle Vectors
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
BR112012024661A2 (pt) 2010-04-01 2015-09-15 Centre Nat Rech Scient composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
BR112013001516A2 (pt) 2010-07-22 2016-06-07 Novartis Ag compostos de tiofeno 2,3,5-trissubstituídos e empregos destes
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2658857B1 (en) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5726155A (en) * 1993-08-02 1998-03-10 The Scripps Research Institute Regulation of oxidative burst using LMWG-derived peptides and analogs
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal

Also Published As

Publication number Publication date
EP0859833A4 (en) 2001-03-28
AU7200796A (en) 1997-04-17
WO1997012033A1 (en) 1997-04-03
US5981247A (en) 1999-11-09
EP0859833A1 (en) 1998-08-26
JPH11514862A (ja) 1999-12-21
ATE318896T1 (de) 2006-03-15
DE69635864D1 (de) 2006-04-27
EP0859833B1 (en) 2006-03-01
DE69635864T2 (de) 2006-10-26
US6248589B1 (en) 2001-06-19
AU719122B2 (en) 2000-05-04
JP4191797B2 (ja) 2008-12-03

Similar Documents

Publication Publication Date Title
EP0859833B1 (en) Recombinant hepatitis c virus rna replicase
WO1997012033A9 (en) Recombinant hepatitis c virus rna replicase
JP3280384B2 (ja) C型肝炎ウイルス(hcv)のns3プロテアーゼの蛋白分解活性のインビトロにおける再生方法
Ishii et al. Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding
Gallinari et al. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus
Gohara et al. Production of “authentic” poliovirus RNA-dependent RNA polymerase (3Dpol) by ubiquitin–protease-mediated cleavage in Escherichia coli
US6326151B1 (en) Screening methods to identify agents that selectively inhibit hepatitis C virus replication
AU717875B2 (en) HCV NS3 protein fragments having helicase activity and improved solubility
Neufeld et al. Purification, characterization, and comparison of poliovirus RNA polymerase from native and recombinant sources.
US6461845B1 (en) Recombinant hepatitis C virus RNA replicase
BLAIR et al. Mutations in the poliovirus 3CD proteinase S1-specificity pocket affect substrate recognition and RNA binding
Shoji et al. Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli
Morrow et al. Antibody to a synthetic nonapeptide corresponding to the NH2 terminus of poliovirus genome-linked protein VPg reacts with native VPg and inhibits in vitro replication of poliovirus RNA
US6815159B2 (en) Purified active HCV NS2/3 protease
Zhong et al. Nucleoside triphosphatase and RNA helicase activities associated with GB virus B nonstructural protein 3
Cho et al. Expression of recombinant HBV Pol proteins in HepG2 cells
Luo Expression of an active hepatitis C virus serine proteinase in E. coli
JPWO1999043792A1 (ja) ヒトc型肝炎ウイルスのrna依存性ポリメラーゼ活性を有する組換え型タンパク及びその製造方法
WO1999043792A1 (en) Recombinant protein having rna-dependent polymerase activity of human hepatitis c virus and process for producing the same
KR19980069020A (ko) 히스티딘이 표지된 한국형 c 형 간염 바이러스의 비구조 단백질 3-4a 및 그의 제조방법

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued